Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sd-0006. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 known ✓ | Q16539 | 19/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 19/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.75 |
| ▸ | EGFR | P00533 | 1/20 | 0.75 |
| ▸ | PRKACA | P17612 | 1/20 | 0.75 |
| ▸ | FRK | P42685 | 1/20 | 0.75 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.75 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.75 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.75 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sd-0006 SCHEMBL5258003 | 0.99 | MAPK11 (0.98) | MAPK11MAPK14MAP4K4EGFRPRKACA | |
| Sd-0006 SCHEMBL5698573 | 0.98 | MAPK11 (0.96) | MAPK11MAPK14MAP4K4EGFRPRKACA | |
| SCHEMBL14411827 | 0.94 | MAPK11 (0.88) | MAPK11MAPK14MAP4K4EGFRPRKACA | |
| SCHEMBL5257721 | 0.92 | MAPK11 (1.00) | MAPK11MAPK14MAP4K4EGFRPRKACA | |
| SCHEMBL5255330 | 0.91 | MAPK11 (0.83) | MAPK11MAPK14MAP4K4EGFRPRKACA | |
| SCHEMBL6175733 | 0.89 | MAPK11 (0.81) | MAPK11MAPK14MAP4K4EGFRPRKACA | |
| SCHEMBL5256729 | 0.89 | MAPK11 (0.80) | MAPK11MAPK14MAP4K4EGFRPRKACA | |
| Water SCHEMBL6173865 | 0.89 | MAPK11 (0.79) | MAPK11MAPK14MAP4K4EGFRPRKACA | |
| SCHEMBL5256675 | 0.88 | MAPK11 (0.79) | MAPK11MAPK14MAP4K4EGFRPRKACA | |
| Hydrochloric Acid SCHEMBL6174383 | 0.86 | MAPK11 (0.78) | MAPK11MAPK14MAP4K4EGFRPRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | claimed |
| EP-3069732-B1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | THE DOSHISHA (JP) | 2023-07-12 | — | — | EP | claimed |
| EP-3553169-B1 | NORMALIZATION OF CULTURE OF CORNEAL ENDOTHELIAL CELLS | KYOTO PREFECTURAL PUBLIC UNIV CORP (JP) | 2021-11-03 | — | — | EP | claimed |
| US-20160331736-A1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | THE DOSHISHA (JP) | 2016-11-17 | — | — | US | claimed |
| EP-3069732-A1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | The Doshisha (JP) | 2016-09-21 | — | — | EP | claimed |
| JP-2005508911-A | — | — | 2005-04-07 | — | — | JP | claimed |
| US-6872725-B2 | Solid-state forms of N-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidinyl)-3-(4-chlorophenyl) pyrazole | PHARMACIA CORPORATION (US) | 2005-03-29 | — | — | US | claimed |
| EP-1429773-A1 | PROCESS FOR MAKING SUBSTITUTED PYRAZOLES | Pharmacia Corporation (US) | 2004-06-23 | — | — | EP | claimed |
| EP-1429772-A1 | N-(2-HYDROXYACETYL)-5-(4-PIPERIDYL)-4-(4-PYRIMIDINYL)-3-(4-CHLOROPHENYL)PYRAZOLE | Pharmacia Corporation (US) | 2004-06-23 | — | — | EP | claimed |
| US-20030153583-A1 | Solid-state forms of N-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidinyl)-3-(4-chlorophenyl) pyrazole | PHARMACIA CORPORATION | 2003-08-14 | — | — | US | claimed |
| US-20030144302-A1 | Process for making substituted pyrazoles | PHARMACIA CORPORATION | 2003-07-31 | — | — | US | claimed |
| WO-2003026662-A1 | SOLID-STATE FORMS OF N-(2-HYDROXYACETYL)-5-(4-PIPERIDYL)-4-(4-PYRIMIDINYL)-3-(4-CHLOROPHENYL)PYRAZOLE | PHARMACIA CORPORATION (US) | 2003-04-03 | — | — | WO | claimed |
| WO-2003026663-A1 | PROCESS FOR MAKING SUBSTITUTED PYRAZOLES | PHARMACIA CORPORATION (US) | 2003-04-03 | — | — | WO | claimed |
| EP-4648772-A1 | MEDICINAL PRODUCTS AND METHODS FOR THE ALLEVIATION OF CANCER IMMUNOTHERAPY-ASSOCIATED CYTOKINE RELEASE SYNDROME | Poolbeg Pharma (UK) Limited (GB) | 2025-11-19 | — | — | EP | disclosed |
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | disclosed |
| WO-2024150014-A1 | MEDICINAL PRODUCTS AND METHODS FOR THE ALLEVIATION OF CANCER IMMUNOTHERAPY-ASSOCIATED CYTOKINE RELEASE SYNDROME | Poolbeg Pharma (UK) Limited (GB) | 2024-07-18 | — | — | WO | disclosed |
| WO-2003026662-A1 | SOLID-STATE FORMS OF N-(2-HYDROXYACETYL)-5-(4-PIPERIDYL)-4-(4-PYRIMIDINYL)-3-(4-CHLOROPHENYL)PYRAZOLE | PHARMACIA CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| US-6525059-B1 | Mitogen-activated protein kinases (MAP); | G. D. SEARLE & COMPANY | 2003-02-25 | — | — | US | disclosed |
| EP-1144403-A1 | SUBSTITUED PYRAZOLES AS P38 KINASE INHIBITORS | G.D. SEARLE & CO. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000031063-A1 | SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS | G.D. SEARLE & CO. (US) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153583-A1 | Solid-state forms of N-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidinyl)-3-(4-chlorophenyl) pyrazole | MAP4K2, MAPK1, MAPKAPK2 | MAPK14 16/4885MAPK11 71/4885MAP4K4 9/4885 |
| US-20030144302-A1 | Process for making substituted pyrazoles | CYP4F3, CYP3A4, TH | MAPK14 2027/4885MAPK11 1387/4885MAP4K4 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.